Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Community Study to Increase Mammogram Screening Among Overdue Women (IMPLEMENT)

16. september 2026 opdateret af: National University Hospital, Singapore

A Community-Based Implementation Study of Pragmatic Interventions to Improve Mammography Uptake in Non-Screen Adherent Women

Breast cancer is the most common cancer among women in Singapore, and regular mammogram screening can detect breast cancer early when treatment is more effective. However, many eligible women do not attend regular mammogram screening despite national screening programs and free screening for eligible women enrolled in Healthier SG.

The IMPLEMENT Study is a community-based implementation study that will evaluate whether practical, low-cost behavioural interventions can increase mammogram screening among women who are overdue for screening or have never been screened. The interventions have previously been shown to be effective in randomized controlled trials conducted by the study team.

The study will be conducted in the Health District @ Queenstown (HD@QT). Women living in Happy Village @ Mei Ling will receive one behavioural intervention that has been shown to be effective in a previous randomized trial, while eligible women living in the remainder of HD@QT will receive usual care with no study intervention. Different implementation trials will be conducted for different screening populations, including women who have never undergone mammography, women who are overdue for repeat mammography, and women who are due for their next mammogram.

The primary objective is to determine whether implementing these evidence-based interventions in a real-world community setting increases the proportion of women completing mammography within four months. Results from this study will help determine whether these interventions can be integrated into community health programs to improve breast cancer screening participation in Singapore.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

15000

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Singapore, Singapore
        • National University Hospital Singapore

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

50 år til 69 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Inclusion Criteria:

  • Singaporean citizen
  • Age 50-69 years
  • Registered patients of NUHS
  • No history of breast cancer
  • Eligible for free mammograms (Signed up with Healthier SG with a primary care provider within the NUHS Primary Care Network)
  • In each individual trial in this proposed series of trials, the participants will either be:

Repeat screeners: Have undergone a mammogram at least once in the past, but not within the past 2 years Never screeners: Have never done mammogram in the past (no records in EPIC) Active screeners: Have undergone a mammogram within the past 20-24 months but have not scheduled their next screening in Health Appointment System (HAS)

Exclusion Criteria:

  • Diagnosis of breast cancer in EPIC
  • Pregnant woman

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Sundhedstjenesteforskning
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Evidence-based behavioural intervention

Eligible women residing in Happy Village @ Mei Ling will receive the evidence-based behavioural intervention specified for their screening population. The intervention will be implemented in the community to increase mammography completion within four months. In Trial A on defaulted repeats screeners the intervention will be Mailed Reminder (MR) with dedicated hotline scheduling. In Trial 2 on never-screeners the intervention will be MR with Prescheduled Appointment.

Evidence-based behavioural intervention delivered to eligible women in Happy Village @ Mei Ling to encourage mammography screening. The specific intervention, delivery method, frequency, and duration will be defined for each screening population based on the corresponding previous randomized trial. In Trial 1 the intervention will be mailed reminder (MR) with dedicated appointment scheduling hotline. In Trial 2, the intervention will be MR with prescheduled appointment.

Ingen indgriben: Comparator group

Eligible women residing in the remainder of HD@QT will receive usual care without the study-delivered behavioural intervention. Mammography completion will be assessed using the same outcome definition and follow-up period.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of eligible women who complete mammography within four months of intervention delivery.
Tidsramme: 4 month

This community-based implementation study will evaluate the effectiveness of evidence-based behavioural interventions to increase mammography screening in eligible women residing in the Health District @ Queenstown. Eligible women living in Happy Village @ Mei Ling will receive the intervention assigned to their screening population, while eligible women living in the remainder of the health district will receive usual care. The study will include implementation cohorts of women who have never undergone mammography, women who are overdue for repeat mammography, and women who are due for their next mammogram. The intervention will be delivered in parallel to usual care, and allocation will be non-randomized based on residential location. Mammography completion will be assessed within four months of intervention delivery.

4 month

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time from mailed reminder to mammography completion
Tidsramme: From mailer delivery through 4 months.

Time from intervention mailer delivery to completion of mammography, measured in days.

From mailer delivery through 4 months.
Time to appointment booking
Tidsramme: From mailer delivery through 4 months.

Time from intervention mailer delivery to the first mammography appointment booking, measured in days.

From mailer delivery through 4 months.

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Factors associated with mammography completion
Tidsramme: Baseline participant characteristics; mammography completion assessed within 4 months

Exploratory analysis of the association between age, ethnicity, housing type, prior mammography history, and time since last mammogram, and mammography completion.

Baseline participant characteristics; mammography completion assessed within 4 months
Mammography appointment no-show rate
Tidsramme: From first appointment booking through 4 months after mailer delivery.

Proportion of booked mammography appointments not attended, among participants with available appointment attendance data.

From first appointment booking through 4 months after mailer delivery.
Number of participants attending Happy Village outposts
Tidsramme: From intervention delivery through 4 months.

Number of participants in the implementation group who attend Happy Village outposts for screening-related support or services.

From intervention delivery through 4 months.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. november 2026

Primær færdiggørelse (Anslået)

1. november 2028

Studieafslutning (Anslået)

31. december 2029

Datoer for studieregistrering

Først indsendt

16. september 2026

Først indsendt, der opfyldte QC-kriterier

16. september 2026

Først opslået (Faktiske)

22. september 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

22. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. september 2026

Sidst verificeret

1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2026-0741

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner